Document Detail

Antiretroviral treatment cohort analysis using time-updated CD4 counts: assessment of bias with different analytic methods.
Jump to Full Text
MedLine Citation:
PMID:  22114687     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Survival analysis using time-updated CD4+ counts during antiretroviral therapy is frequently employed to determine risk of clinical events. The time-point when the CD4+ count is assumed to change potentially biases effect estimates but methods used to estimate this are infrequently reported.
METHODS: This study examined the effect of three different estimation methods: assuming i) a constant CD4+ count from date of measurement until the date of next measurement, ii) a constant CD4+ count from the midpoint of the preceding interval until the midpoint of the subsequent interval and iii) a linear interpolation between consecutive CD4+ measurements to provide additional midpoint measurements. Person-time, tuberculosis rates and hazard ratios by CD4+ stratum were compared using all available CD4+ counts (measurement frequency 1-3 months) and 6 monthly measurements from a clinical cohort. Simulated data were used to compare the extent of bias introduced by these methods.
RESULTS: The midpoint method gave the closest fit to person-time spent with low CD4+ counts and for hazard ratios for outcomes both in the clinical dataset and the simulated data.
CONCLUSION: The midpoint method presents a simple option to reduce bias in time-updated CD4+ analysis, particularly at low CD4 cell counts and rapidly increasing counts after ART initiation.
Authors:
Katharina Kranzer; James J Lewis; Richard G White; Judith R Glynn; Stephen D Lawn; Keren Middelkoop; Linda-Gail Bekker; Robin Wood
Related Documents :
20064887 - Factors associated with posttraumatic growth among the spouses of myocardial infarction...
22019377 - Development and evaluation of an ontology for guiding appropriate antibiotic prescribing.
15967177 - The structure of disgust: domain specificity in relation to contamination ideation and ...
20134897 - Der einfluss der szintillation auf den faktor k der sonnenfleckenrelativzahl.
11756277 - A model of lamina digestibility of orchardgrass as influenced by nitrogen and defoliation.
15684227 - Crosschip: a system supporting comparative analysis of different generations of affymet...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2011-11-17
Journal Detail:
Title:  PloS one     Volume:  6     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2011  
Date Detail:
Created Date:  2011-11-24     Completed Date:  2012-05-03     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e27763     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-HIV Agents / therapeutic use*
Antiretroviral Therapy, Highly Active*
Bias (Epidemiology)
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes / drug effects*
Cohort Studies
Computer Simulation
HIV Infections / drug therapy*,  immunology*,  virology
Humans
South Africa
Treatment Outcome
Tuberculosis / drug therapy,  virology
Viral Load
Grant Support
ID/Acronym/Agency:
087262/Z/08/Z//Wellcome Trust; 088590/Z/09/Z//Wellcome Trust; 1U19AI53217/AI/NIAID NIH HHS; 1U19AI53217-01/AI/NIAID NIH HHS; 5 R01 AI058736-02/AI/NIAID NIH HHS; 5U01AI069924-02/AI/NIAID NIH HHS; G0802414//Medical Research Council; IU19AI53217-07/AI/NIAID NIH HHS; R01 AI058736/AI/NIAID NIH HHS; U01 AI069924/AI/NIAID NIH HHS; U19 AI053217/AI/NIAID NIH HHS; WT084323MA//Wellcome Trust
Chemical
Reg. No./Substance:
0/Anti-HIV Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS One
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
ISSN: 1932-6203
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Kranzer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received Day: 2 Month: 9 Year: 2011
Accepted Day: 24 Month: 10 Year: 2011
collection publication date: Year: 2011
Electronic publication date: Day: 17 Month: 11 Year: 2011
Volume: 6 Issue: 11
E-location ID: e27763
ID: 3219676
PubMed Id: 22114687
Publisher Id: PONE-D-11-17335
DOI: 10.1371/journal.pone.0027763

Antiretroviral Treatment Cohort Analysis Using Time-Updated CD4 Counts: Assessment of Bias with Different Analytic Methods Alternate Title:Cohort Analysis Using Time-Updated CD4 Counts
Katharina Kranzer12*
James J. Lewis34
Richard G. White3
Judith R. Glynn3
Stephen D. Lawn12
Keren Middelkoop25
Linda-Gail Bekker25
Robin Wood25
Matthew P. Foxedit1 Role: Editor
1Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
2The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa
3Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
4Aurum Institute for Health Research, Johannesburg, South Africa
5Department of Medicine, Faculty of Health Science, University of Cape Town, Cape Town, South Africa
Boston University, United States of America
Correspondence: * E-mail: katharina.kranzer@lshtm.ac.uk
Contributed by footnote: Conceived and designed the experiments: KK JJL. Performed the experiments: KK KM LGB RW. Analyzed the data: KK JJL RGW. Contributed reagents/materials/analysis tools: RW LGB KM SDL KK JJL RGW JRG. Wrote the paper: KK JJL RDW SDL RGW.

Introduction

Observational prospective cohort data of patients on antiretroviral therapy (ART) are often used to estimate the relationship between time-varying CD4+ counts and incident clinical events such as tuberculosis (TB), death, opportunistic infections and malignancies. These studies aim to investigate the effect of actual CD4+ count on morbidity and mortality by using time-varying measures. While within-subject CD4+ count variability [1], [2], [3] will inevitably introduce measurement error, measurement frequency and the choice of when to split time attributed to a certain CD4+ count value might also introduce bias. Measurement frequencies are either determined by the study protocol which specifies time intervals at which individuals are followed (interval cohort) or by prevailing guidelines within the health care service (clinical cohort) [4]. In the latter the frequency of visits and laboratory measurements may also be influenced by the severity of illness, access to and utilization of health care which might increase the bias.

Differences in measurement frequency between two exposure groups have been shown to introduce bias when time to a specific biomarker level is used as a surrogate outcome [5]. The time-point when the CD4+ count is assumed to change might bias effect estimates especially when measurement intervals are wide or CD4+ counts are rapidly changing. A literature review of studies published between January 2006 and August 2010 investigating the effect of time-updated CD4+ counts on mortality and morbidity found that the majority (11/21) of studies did not did not specify the method used to estimate the time-point of change (table 1). Of remaining studies, eight assumed that the CD4+ count remains constant until the date of the next measurement and two studies used linear interpolation between two consecutive CD4+ count measurements to provide a midpoint measurement and time-point.

We aimed to assess how different methods of dealing with time points influence effect estimates and rates using data from a clinical ART cohort with frequent measurements. We used the two methods most frequently used in the literature and investigated the effect of a third method assuming that the CD4+ count remains constant from the midpoint of the preceding interval until the midpoint of the subsequent interval.

The clinical ART cohort used for this study was based in Cape Town, South Africa and CD4+ counts were measured monthly for the first 3 months and 3 monthly thereafter. We also investigated the direction of bias using a simulated dataset.


Methods
Data collection

Data collected in a peri-urban township in the greater area of Cape Town as part of the CIPRA-SA trial were used for this analysis [6]. The trial randomized patients to nurse or doctor-monitored HIV care and showed equivalence of the two monitoring strategies for treatment failure over 2 years. A total of 363 HIV-positive ART-naïve patients with a CD4 cell count of ≤350 cell/uL or WHO stage 4 disease from this study community were enrolled in the trial in Cape Town. All patients received a standard ART regimen and were managed according to the South African National Guidelines [7].

CD4+ counts were measured at weeks −4, 0, 4, 8, 12 (relative to the start of ART) and then every 12 weeks. Incident TB was used as the outcome of interest. Start and end of TB treatment were determined by merging the ART register with the electronic TB register on first name, surname, medical record number, date of birth, truncation of names and switching of first name and surname. This method was validated by clinical folder review in a similar dataset of 585 patients from a different study and revealed 96.1% sensitivity and 97.4% specificity. All identifiers were removed from the data after merging.

Individuals who did not live in the study community and individuals who were on TB treatment at ART initiation and died or were lost to follow-up before they completed treatment were excluded from the analysis.

The exposure was time-updated CD4+count and the outcome was incident TB defined as starting TB treatment. Person-time accrued from ART initiation to the date of TB disease, death, becoming lost to follow-up or the 31st December 2008 was calculated. Individuals who were on TB treatment at time of ART initiation were only included in the analysis after they had completed TB treatment. Individuals who developed incident TB were re-included in the analysis after completing TB treatment. Individuals only contributed time while they were on ART and person-time while defaulting care was excluded from the analysis, as neither the exposure (CD4+ count) not the outcome (TB) was known for these periods.

Time-updated CD4 count

The data were analyzed in three different ways: the first analysis assumed that the CD4+ count changed at the date when the blood sample for CD4+ count measurement was drawn (date of measurement analysis) (figure 1A); the second assumed a change of CD4+count at the midpoint between two measurements (midpoint analysis) (figure 1B); and the third calculated an additional CD4+ count using a linear interpolation between two consecutive CD4+ measurements and used the date when the blood samples were drawn and the midpoint between the two dates as the time point of change of CD4+ count (linear interpolation analysis) (figure 1C).

Newly generated datasets

A dataset including baseline CD4+ counts and 6-monthly CD4+ counts only was generated. From this dataset 15% of the follow-up CD4+ counts were randomly selected and removed to simulate the reality of missing data in clinical cohorts. A total of 100 datasets with 15% randomly missing follow-up CD4+ counts were generated.

Gold standard dataset

The effect estimates and person-time using the newly generated dataset with 6-monthly CD4+ counts and different methods to estimate time-point of change were compared with results obtained when analysing the dataset using all available CD4+ counts (gold standard dataset). The gold standard dataset included CD4+ counts measured on a monthly bases from 0–3 months on ART, followed by 3-monthly CD4+ counts until death, loss-to-follow up, transfer out or censoring. Table 2 shows the difference in median CD4+ counts over time in the gold standard dataset and the 6-monthly dataset using different methods to estimate the time-point of CD4+ change.

Statistical analysis

All analyses were carried out using Stata version 11.0 (Stata Corp. LP, College Station, TX, United States of America). The association between time-updated CD4+ count and TB was explored describing the rate of incident TB and using crude Kaplan-Meier curves. Cox proportional hazard regression was used to model the relationship between time-updated CD4+ count and TB. Hazard proportionality was assessed by analysis of scaled Schoenfeld residuals.

Events, person-time, rates, hazard ratios and standard errors were determined for the 100 datasets with 15% randomly missing follow-up data. The overall estimates were calculated according to the combination rules described by Rubin [8].

Simulated CD4+ dataset

Simulated CD4+ count data by time since treatment initiation and baseline CD4+ strata, , were generated by fitting to empirical data from Nash et al.[9] by least-squares, where was the CD4+ stratum at treatment initiation, was time since treatment initiation, was the average CD4+ level in strata at treatment initiation, was a parameter determining the increase in CD4+ count in strata after 5 years of treatment, and was a parameter determining the rate of CD4+ count increase in strata . Each CD4+ stratum was simulated separately and the results were also combined to generate a ‘mixed’ cohort of 25%, 17%, 18%, 15%, 25% of patients with baseline CD4+ of 25–50 cells/uL, 51–100 cells/uL, 101–150 cells/uL, 151–200 cells/uL and 201–300 cells/uL respectively, to represent a mix of patients seen in a typical clinic. A clinical South African ART cohort was used to determine the proportions of patients in different CD4+ count strata for the mixed cohort [10].

The areas under the CD4+ curve (AUC) were calculated using date of measurement, midpoint or linear interpolation methods with either 6 monthly or 3 monthly measurements. The AUC measures CD4 exposure. It is derived from the actual CD4+ values and the time spent with these values. Rates were calculated assuming constant rates within CD4+ count strata using TB rate estimates from published literature [11], [12].

Ethical approval

All patients in the CIPRA-SA trial signed informed consent forms. The trial was approved by the University of Cape Town Ethics Committee and Partners Human Subjects Institutional Review Board. The London School of Hygiene and Tropical Medicine Ethics Committee and the University of Cape Town Ethics Committee and Partners Human Subjects Institutional Review Board gave approval for the analysis of the anonymised data.


Results
TB incidence and hazard ratios by time-updated CD4+ count using clinical cohort data

Overall TB incidence was 4.9/100 person–years (PY) (95% confidence interval (CI) 3.6–6.8). TB incidence rates were 14.7 in the lowest CD4+ count stratum (≤200 cells/uL), 3.1 in the middle CD4+ count stratum (201–350 cells/uL) and 2.9 in the highest CD4+ count stratum (>350 cells/uL) when using all available CD4+ counts and performing a date of measurement analysis (table 3). The midpoint analysis revealed TB incidence rates of 16.0, 3.1 and 2.8 for the three different CD4+ count categories. The total person-time spent at low CD4+ counts was less in the midpoint analysis compared to the date of measurement analysis.

TB incidence rates and hazard ratios (HRs) were different when using a dataset with 6 monthly CD4+ counts as compared to analysis using all available CD4+ counts (table 3). With all three estimation methods, compared to the results with more frequent measures, rates were underestimated at low and high CD4+ counts, and overestimated at moderate CD4+ counts, with most marked overestimation in the midpoint analysis.

Analyses using a dataset with 6 monthly CD4+ counts and 15% randomly missing follow-up CD4+ counts revealed more extreme variations in rates, but with the same pattern of underestimation at low and high counts, and overestimation at moderate counts (table 3). The differences in rates and HRs compared to the analysis using all available data were most pronounced using the date of measurement analysis, and least pronounced using the midpoint analysis.

Area under the CD4+ curve using simulated data

The midpoint analysis estimated the AUC most accurately for cohorts with low (25–50 cell/uL), high (151–200 cells/uL) and mixed baseline CD4+ counts (table 4). The date of measurement analysis underestimated the AUC for all cohorts and time-points. The relative difference was most pronounced in cohorts with low baseline CD4 counts and short follow-up (1 year). The date of measurement analysis was less accurate with 3 monthly measurements than the midpoint analysis with 6 monthly measurements.

TB rates using simulated data

Both the date of measurement and midpoint analysis underestimated TB rates for low CD4+ count strata (<200 cell/uL). Rates were less accurately estimated using the date of measurement analysis compared to the midpoint analysis (table 5). Rates for some CD4 count+ strata could not be determined as no time was spent in those strata. For example a cohort with a baseline CD4 count of 151–200 did not accumulate any person-time in the CD4+ count strata ≤50 and 51–100. In addition cohorts with baseline CD4+ counts of 25–50 and 51–100 did not improve their CD4+ count beyond 400 over the 5 year period and thus did not accumulate any time in higher CD4+ count strata.


Discussion

This study shows that the time-point when a CD4+ count is assumed to change influences incidence rates of clinical events during ART and effect estimates in time-updated CD4+ count analysis. The analysis using modeled CD4+ count data showed that the midpoint method gives a better approximation of person-time spent at low CD4+ counts compared to the date of measurement method. The choice of time-point when a CD4+ count is assumed to change had the greatest impact in cohorts with low baseline CD4+ counts and during the first year after ART initiation. While the absolute difference in effect estimates was small when analyzing data with frequent measurements, the choice of time-point was important in data with less frequent and missing measurements. Thus the frequency of measurement and the method used to determine the time-point of change in CD4+ count need to be taken into account when comparing effect estimates from different studies. However, most studies performing survival or Cox regression analysis with time-updated CD4+ count as exposure or confounder variable fail to describe how the time-point of change in CD4+ count was determined [13], [14], [15], [16], [17], [18], [19], [20], [21], [22].

The rate of change in CD4+ count is highest in the first months after initiation of ART [9]. The dataset including all CD4+ counts had a particularly high frequency of measurements in the first three months on ART, with testing done at 0, 4, 8 and 12 weeks. Person-time spent with low CD4+ counts was overestimated in all analyses conducted on a dataset with only 6 monthly CD4+ counts compared to analysis using a dataset with all available CD4+ counts. As a result TB incidence rates were underestimated in the low CD4+ count strata. The difference in person-time spent with low CD4+ counts was smallest in the midpoint analysis, but rates and hazard ratios were nevertheless strongly biased using the dataset with 6-monthly CD4+ counts. The bias was due to a smaller number of events estimated to occur in the low CD4+ count strata, which was probably due to chance and small sample size. The analysis using modeled CD4+ count data showed that the midpoint analysis estimated person-time and rates most accurately. The linear interpolation method estimated person-time and rates more accurately compared to the date of measurement, but less so when compared to the midpoint methods. However, more than one interpolation or possibly daily interpolation is likely to improve the accuracy of these estimates.

Our study confirms and extends the findings of a study from Côte d’Ivoire [23]. In this study by Deuffic-Bruban et al., person-time spent at low CD4+ counts (<50 cells/uL) was highest in the date of measurement analysis and lowest in the analysis assuming that the CD4+ count changed immediately to the level of the next measurement [23]. Estimates of rates of opportunistic infections were highest (249/100 PYs) in the analysis assuming an immediate change, followed by the linear interpolation (210/100 PYs) and date of measurement analysis (130/100 PYs). However this study is not comparable to our study or to routine programmatic data because of the very high frequency of CD4+ counts (median time between the last CD4+ measurements 1–1.8 months) throughout the study (compared to a median of 3 months in our study) which means that the differences between methods will be less pronounced. Deufic-Burban et al. did not compare the results from the original dataset and datasets with less frequent measurements and thus they were unable to assess the extent of bias that would be seen in those situations. In contrast, we used the dataset with frequent measurements as a gold standard and compared it to a generated dataset with only 6-monthly measurements (a dataset comparable to most clinical cohort data). Another further important addition in our study was that we used the midpoint method. This method gave a good approximation to the time spent at low CD4+ count strata.

Most analyses investigating the effect of time-updated CD4+ counts on clinical outcomes use CD4+ count categories [14], [19], [21], [24], [25]. Categorizing a continuous variable such as CD4+ count increases the problem of misclassification since small differences can result in a change in category. Bias introduced by categorization needs to be taken into account when analyzing and interpreting the results from time-updated CD4+ count analysis. Limitations of the clinical cohort analysis are the small sample size, the small number of events and the relatively high baseline CD4+ count. The effect estimates calculated in full analysis were imprecise and the extent of bias due to different methods was uncertain from the clinical cohort analysis alone. However the analysis using modeled data confirmed that person-time at higher CD4+ counts and rates were more profoundly underestimated using the date of measurement method compared to the midpoint method. Missing data was randomly missing in the newly created datasets. This is unlikely to be the case in clinical cohorts, where missingness could be more likely in healthy patients with fewer scheduled visits or sicker patients due to difficulties in accessing care. TB rates within CD4+ count strata were assumed constant in the modeled dataset which might not accurately reflect the reality. Thus estimated TB rates might be even more biased if true TB rates differ according to CD4+ count within CD4+ count strata.

Analysis using time-updated CD4+ counts as exposure or confounder should consider using the midpoint method as a simple way to reduce bias. In addition authors should be encouraged to clearly describe the assumption underlying the time-point of change in CD4+ count and researchers conducting meta-analyses should contact authors to determine the method used.


Notes

Competing Interests: The authors have declared that no competing interests exist.

Funding: KK (087262/Z/08/Z) and SDL (088590/Z/09/Z) are funded by the Wellcome Trust, London, United Kingdom. RGW is funded by a Medical Research Council (UK) Methodology Research Fellowship (G0802414), the Bill and Melinda Gates Foundation (19790.01), and the EU FP7 (242061). JJL is funded by the Consortium to Respond Effectively to the AIDS TB Epidemic, United States, funded by the Bill and Melinda Gates Foundation. RW is funded by IEDEA (International epidemiologic Databases to Evaluate AIDS) (5U01AI069924-02, CEPAC (Cost Effectiveness of Preventing AIDS Complications) (5 R01 AI058736-02), USAID Right to Care (CA 674 A 00 08 0000 700), CIPRA (Comprehensive International Programme of Research on AIDS) (IU19AI53217-07). LGB is funded by the National Institutes of Health (NIH) CIPRA (Comprehensive International Programme of Research on AIDS) (1U19AI53217). KM is funded by the NIH CIPRA (Comprehensive International Programme of Research on AIDS) (1U19AI53217), Wellcome Trust Strategic award CIDRI, Cape Town (WT084323MA). Funding for the CIPRA-SA trial was provided by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, through the grant number 1U19AI53217-01. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

References
1. Hughes MD,Stein DS,Gundacker HM,Valentine FT,Phair JP,et al. Year: 1994Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring.J Infect Dis16928367903975
2. Raboud JM,Montaner JS,Conway B,Haley L,Sherlock C,et al. Year: 1996Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection.J Infect Dis1741911948655993
3. Guarner J,Montoya P,del Rio C,Hernandez-Tepichin G. Year: 1997CD4+ T-lymphocyte variations in patients with advanced human immunodeficiency virus infection and counts below 100 cells per microliter.Cytometry301781809298835
4. Lau B,Gange SJ,Moore RD. Year: 2007Interval and clinical cohort studies: epidemiological issues.AIDS Res Hum Retroviruses2376977617604539
5. Griffin JT,Fraser C,Gras L,de Wolf F,Ghani AC. Year: 2006The effect on treatment comparisons of different measurement frequencies in human immunodeficiency virus observational databases.Am J Epidemiol16367668316484448
6. Sanne I,Orrell C,Fox MP,Conradie F,Ive P,et al. Year: 2010Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial.Lancet376334020557927
7. National antiretroviral treatment guidelines, first ed JacanaYear: 2004Pretoria: National Department of Health, South Africa
8. Rubin DB. Year: 1987Multiple Imputation for Nonresponse in Surveys.New YorkJ. Wiley & Sons
9. Nash D,Katyal M,Brinkhof MW,Keiser O,May M,et al. Year: 2008Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.Aids222291230218981768
10. Kranzer K,Lewis JJ,Ford N,Zeinecker J,Orrell C,et al. Year: 2010Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors.J Acquir Immune Defic Syndr55e172320827216
11. Lawn SD,Myer L,Edwards D,Bekker LG,Wood R. Year: 2009Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.AIDS231717172519461502
12. Van Rie A,Westreich D,Sanne I. Year: 2011Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies.J Acquir Immune Defic Syndr5634935520926954
13. Reekie J,Mocroft A,Sambatakou H,Machala L,Chiesi A,et al. Year: 2008Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?AIDS222381239018981778
14. Lodi S,Guiguet M,Costagliola D,Fisher M,de Luca A,et al. Year: 2010Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.Journal of the National Cancer Institute10278479220442214
15. Crum-Cianflone N,Hullsiek KH,Marconi V,Weintrob A,Ganesan A,et al. Year: 2009Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study.AIDS23415019050385
16. Crum-Cianflone N,Hullsiek KH,Satter E,Marconi V,Weintrob A,et al. Year: 2009Cutaneous malignancies among HIV-infected persons.Archives of Internal Medicine1691130113819546414
17. Prosperi MC,Cozzi-Lepri A,Castagna A,Mussini C,Murri R,et al. Year: 2010Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study.Clinical Infectious Diseases501316132120297953
18. Seyler C,Messou E,Gabillard D,Inwoley A,Alioum A,et al. Year: 2007Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis.AIDS Research & Human Retroviruses231338134718184075
19. Walker AS,Ford D,Gilks CF,Munderi P,Ssali F,et al. Year: 2010Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.Lancet3751278128620347483
20. De Beaudrap P,Etard JF,Diouf A,Ndiaye I,Ndeye GF,et al. Year: 2010Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort.BMC Infectious Diseases1017920565900
21. Mocroft A,Ledergerber B,Zilmer K,Kirk O,Hirschel B,et al. Year: 2007Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.AIDS211867187517721094
22. Collaboration of Observational HIVERESG,Bohlius J,Schmidlin K,Costagliola D,Fatkenheuer G,et al. Year: 2009Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.Antiviral Therapy141065107420032536
23. Deuffic-Burban S,Losina E,Wang B,Gabillard D,Messou E,et al. Year: 2007Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Cote d'Ivoire: impact of alternative methods of CD4 count modelling.Eur J Epidemiol2273774417828437
24. Lawn SD,Badri M,Wood R. Year: 2005Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort.Aids192109211616284460
25. Lawn SD,Little F,Bekker LG,Kaplan R,Campbel E,et al. Year: 2009Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa.AIDS2333534219114870
26. Dunn D,Woodburn P,Duong T,Peto J,Phillips A,et al. Year: 2008Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.J Infect Dis19739840418248303
27. Guiguet M,Porter K,Phillips A,Costagliola D,Babiker A. Year: 2008Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART).Open AIDS J23918923700
28. Monforte A,Abrams D,Pradier C,Weber R,Reiss P,et al. Year: 2008HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.AIDS222143215318832878
29. Engels EA,Pfeiffer RM,Landgren O,Moore RD. Year: 2010Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era.Journal of Acquired Immune Deficiency Syndromes: JAIDS547884
30. Guiguet M,Bou,x00E,Cadranel J,Lang JM,et al. Year: 2009Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.Lancet Oncology101152115919818686
31. Podlekareva D,Mocroft A,Kirk O,Reiss P,Aldins P,et al. Year: 2008Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.Scandinavian Journal of Infectious Diseases4090891318609197
32. Sogaard OS,Lohse N,Gerstoft J,Kronborg G,Ostergaard L,et al. Year: 2008Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study.Clinical Infectious Diseases471345135318834317
33. Phillips AN,Gazzard B,Gilson R,Easterbrook P,Johnson M,et al. Year: 2007Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.AIDS211717172117690569
34. Bruyand M,Thiebaut R,Lawson-Ayayi S,Joly P,Sasco AJ,et al. Year: 2009Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.Clinical Infectious Diseases491109111619705973

Figures

[Figure ID: pone-0027763-g001]
doi: 10.1371/journal.pone.0027763.g001.
Figure 1  Illustration of the three different methods of modeling CD4+ count.

In the patient shown, we actually observed 11 CD4+ cell counts over the two years (grey line). We have illustrated what would have been modeled if only the results at 6 month intervals (black diamonds) had been available. Dotted and dashed lines (black) are the CD4+ counts assumed by the three different methods: data of measurement (A), midpoint (B) and linear interpolation (C).



Tables
[TableWrap ID: pone-0027763-t001] doi: 10.1371/journal.pone.0027763.t001.
Table 1  Studies conducting analysis using time-updated CD4+.
Author Journal Outcome CD4+ count Description of how time-updated CD4+ counts were determined.
Dunn[26] JID AIDS or death exposure Follow-up time from the time that each measurement was obtained was censored at the date of the next measurement.
Guiguet[27] Open AIDS J AIDS or death exposure CD4+ counts were modeled using linear interpolation between two measurements.
Lawn[25] AIDS Death exposure Person time was divided into intervals each of which was defined by the CD4+ count measurement at the start of the interval.
Lawn[11] AIDS Tuberculosis exposure Person-time was subdivided into 4-month intervals for analysis. Each interval was defined by theCD4 cell count measurement at the start of the interval.
Reekie[13] Cancer non-AIDS-defining malignancies exposure
d'Arminio Monforte[28] AIDS death from malignancies exposure Each person's follow-up was divided into a series of consecutive 1-months periods, and the individual's status (most recent CD4+ count) was determined.
Lodi[14] J Natl Cancer Inst Kaposi sarcoma exposure
Engels[29] JAIDS Non-Hodgkin Lymphoma exposure We considered the most recent laboratory result “current” until the next measurement.
Crum-Cianflone[16] Arch Intern Med Cutaneous malignancy exposure
Guiguet[30] Lancet Oncology Malignancies exposure Follow-up was divided into consecutive 1-month periods, and time-varying covariables were updated at the beginning of every month. The CD4+ count was linearly interpolated unless ART was started between 2 measurements.
Podlekareva[31] Sand J Infec Dis Fungal infections exposure
Prosperi[17] CID Malignancies exposure
Seyler[18] AIDS Res Human Retroviruses Severe morbidity exposure
Sogaard[32] PLoS one Death from pneumonia confounder CD4+ counts were estimated between measurements by carrying forward the value from the most recent measurement
Walker[19] Lancet Effect of Co-trimoxazole confounder
Crum-Cianflone[15] AIDS Malignancies exposure
Phillips[33] AIDS Death exposure Person time was counted from the time of each qualifying CD4+ count until the next CD4+ count.
Beaudrap[20] BMC Infect Dis AIDS defining illness exposure
Mocroft[21] AIDS Clinical disease progression exposure
Bohlius[22] Antivir Ther Non-Hodgkin Lymphoma exposure
Bruyand[34] CID Malignancies exposure We assumed that the value of the measurement reported at a given follow-up visit remained stable until the next follow-up visit

[TableWrap ID: pone-0027763-t002] doi: 10.1371/journal.pone.0027763.t002.
Table 2  Median CD4 counts and interquartile ranges at baseline, 1, 2, 3, 6, 9 and 12 months follow-up using different methods to estimate the time-point of change of CD4+ count.
Months All available CD4+ counts 6 monthly CD4+ counts only
Date of measurement Midpoint Linear interpolation
0 191.5 (109–256) 191.5 (109–256) 191.5 (109–256) 191.5 (109–256)
1 265 (185.5–365.5) 191.5 (109–256) 191.5 (109–256) 191.5 (109–256)
2 296 (198–381) 191.5 (109–256) 191.5 (109–256) 191.5 (109–256)
3 291.5 (198–380) 191.5 (109–256) 307 (213.5–432.5) 248 (158–324)
6 307 (213.5–432.5) 307 (213.5–432.5) 307 (213.5–432.5) 307 (213.5–432.5)
9 313.5 (213.5–432.5) 307 (213.5–432.5) 333 (236–4447) 318 (222–404)
12 333 (236–4447) 333 (236–4447) 333 (236–4447) 333 (236–4447)

[TableWrap ID: pone-0027763-t003] doi: 10.1371/journal.pone.0027763.t003.
Table 3  Person-time, rates of tuberculosis and hazard ratios for tuberculosis using clinical cohort data and different methods to estimate the time-point of change of CD4+ count.
CD4+ strata (cells/uL) Date of measurement analysis Midpoint analysis Linear interpolation analysis
Survival and Cox regression analysis using all available CD4+ counts
Events PY Rate HR Events PY Rate HR Not performed*
≤200 19 128.9 14.7 1 19 119.0 16.0 1
201–350 8 261.2 3.1 0.26 (0.11–0.61) 8 255.4 3.1 0.25 (0.11–0.55)
>350 11 378.7 2.9 0.34 (0.15–0.75) 11 394.5 2.8 0.29 (0.13–0.65)
Survival and Cox regression analysis using 6 monthly CD4+ counts only
Events PY Rate HR Events PY Rate HR Events PY Rate HR
≤200 22 176.6 12.5 1 18 140.2 12.8 1 20 152.1 13.2 1
201–350 10 256.4 3.9 0.41 (0.19–0.88) 13 246.2 5.3 0.52 (0.25–1.08) 12 261.9 4.6 0.45 (0.22–0.95)
>350 6 335.7 1.8 0.25 (0.06–0.66) 7 382.3 1.8 0.24 (0.09–0.62) 6 354.7 1.7 0.22 (0.08–0.60)
Survival and Cox regression analysis using 6 monthly CD4+ counts and 15% randomly missing
Events PY Rate HR Events PY Rate HR Events PY Rate HR
≤200 16.1 184.7 8.7 1 18.7 145.9 12.8 1 16.1 158.6 10.2 1
201–350 14.5 255.8 5.7 0.86 (0.42–1.77) 12.7 245.9 5.2 0.51 (0.24–1.05) 14.5 262.9 5.5 0.73 (0.35–1.510
>350 7.4 326.2 2.3 0.49 (0.19–1.25) 6.6 374.5 1.8 0.23 (0.09–0.59) 7.4 344.8 2.1 0.40 (0.15–1.02)

*Linear interpolation analysis was not performed for the analysis using all available CD4+ counts, as the result was not expected to differ greatly compared to the date of measurement and midpoint analysis.


[TableWrap ID: pone-0027763-t004] doi: 10.1371/journal.pone.0027763.t004.
Table 4  Estimated area under the CD4+ count curve using simulated data and different methods to estimate the time-point of change of CD4+ count.
Baseline CD4+ count of the cohort Time Cumulative area under the CD4+ count curve
True Date of measurement method 6 monthly CD4+ counts Date of measurement method 3 monthly CD4+ counts Linear interpolation method 6 monthly CD4+ counts Midpoint method 6 monthly CD4 counts
25–50 cells/uL 1 year 145 99 123 120 142
5 years 1348 1272 1311 1307 1342
51–100 cells/uL 1 year 180 138 160 157 177
5 years 1435 1368 1403 1399 1430
101–150 cells/uL 1 year 228 186 208 205 225
5 years 1662 1597 1631 1627 1657
151–200 cells/uL 1 year 282 238 261 258 278
5 years 1862 1801 1833 1829 1856
201–300 cells/uL 1 year 345 305 326 323 342
5 years 2180 2121 2152 2148 2274
Mixed 1 year 237 194 216 213 233
5 years 1704 1639 1673 1669 1699

[TableWrap ID: pone-0027763-t005] doi: 10.1371/journal.pone.0027763.t005.
Table 5  Estimated rates of tuberculosis using simulated data and different methods to estimate the time-point of change of CD4+ count.
CD4+ strata True rates Cohort with baseline CD4+ count 25–50 cells/uL Cohort with baseline CD4+ count 51–100 cells/uL Cohort with baseline CD4+ count 151–200 cells/uL Mixed cohort
Date of measurement method Midpoint method Date of measurement method Midpoint method Date of measurement method Midpoint method Date of measurement method Midpoint method
≤50 21.7 11.25 13.2 -- -- -- -- -- --
51–100 12.8 -- -- 9.69 10.12 -- -- -- --
101–200 9.27 6.65 9.27 6.24 8.13 5.93 6.39 7.38 9.27
201–300 5.48 5.42 5.73 5.39 5.48 4.75 5.18 5.48 5.48
301–400 4.61 4.61 4.61 4.61 4.65 4.51 4.59 4.61 4.66
401–500 4.23 -- -- -- -- 4.23 4.23 -- --


Article Categories:
  • Research Article
Article Categories:
  • Biology
    • Microbiology
      • Virology
        • Antivirals
Article Categories:
  • Medicine
    • Clinical Research Design
      • Cohort Studies
    • Diagnostic Medicine
      • Test Evaluation
    • Epidemiology
      • Epidemiological Methods
      • Infectious Disease Epidemiology
    • Infectious Diseases
      • Sexually Transmitted Diseases
        • AIDS
      • Viral Diseases
        • HIV
          • HIV clinical manifestations


Previous Document:  FDA-approved drugs that protect mammalian neurons from glucose toxicity slow aging dependent on cbp ...
Next Document:  Loss of keratin 8 phosphorylation leads to increased tumor progression and correlates with clinico-p...